Akero Therapeutics to Present at Upcoming Healthcare Conferences in September
31 Agosto 2023 - 6:00AM
Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage
company developing transformational treatments for patients with
serious metabolic diseases marked by high unmet medical need, today
announced that management will present at the following investor
conferences this month:
- Morgan Stanley Annual Global Healthcare Conference: Fireside
chat on Tuesday, September 12 at 4:55 p.m. ET
- H. C. Wainwright 25th Annual Global Investment Conference:
Fireside chat on Wednesday, September 13 at 9:00 a.m. ET
Live webcasts of the Company presentations will be available
through the investor relations section of the Company's website
at www.akerotx.com. Following the live webcasts, archived
replays will be available on the Company's website.
About Akero TherapeuticsAkero Therapeutics is a
clinical-stage company developing transformational treatments for
patients with serious metabolic diseases marked by high unmet
medical need, including NASH, a disease without any approved
therapies. Akero's lead product candidate, EFX, is a differentiated
Fc-FGF21 fusion protein that has been engineered to mimic the
balanced biological activity profile of native FGF21, an endogenous
hormone that alleviates cellular stress and regulates metabolism
throughout the body. EFX is designed to offer convenient
once-weekly subcutaneous dosing. The consistency and magnitude of
observed effects position EFX to be a potentially best-in-class
medicine, if approved, for treatment of NASH. EFX is currently
being evaluated in two Phase 2b clinical trials: the HARMONY study
in patients with pre-cirrhotic NASH (F2-F3 fibrosis), and the
SYMMETRY study in patients with cirrhotic NASH (F4 fibrosis,
compensated). EFX has also been evaluated in an expansion cohort of
the SYMMETRY study, Cohort D, comparing the safety and tolerability
of EFX to placebo when added to an existing GLP-1 receptor agonist
in patients with pre-cirrhotic NASH (F1-F3 fibrosis) and Type 2
diabetes, for which topline results were reported on June 5, 2023.
Akero is headquartered in South San Francisco. Visit us
at akerotx.com and follow us
on LinkedIn and Twitter for more
information.
Investor Contact:Christina TartagliaStern
Investor Relations,
Inc.212.362.1200christina.tartaglia@sternir.com
Media Contact:Sarah O'ConnellVerge Scientific
Communications732.456.0092soconnell@vergescientific.com
Akero Therapeutics (NASDAQ:AKRO)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Akero Therapeutics (NASDAQ:AKRO)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024